share_log

Is ICL Group (NYSE:ICL) A Risky Investment?

Is ICL Group (NYSE:ICL) A Risky Investment?

以色列化學集團(NYSE:ICL)是否是一項風險投資?
Simply Wall St ·  2024/11/19 07:37

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. Importantly, ICL Group Ltd (NYSE:ICL) does carry debt. But should shareholders be worried about its use of debt?

傳奇基金經理李錄(查理·芒格曾支持他)曾說過:'最大投資風險不是價格波動,而是你是否會遭受資本的永久損失。' 因此,聰明的錢知道,債務——通常與破產有關——在評估一家公司風險時是一個非常重要的因素。重要的是,以色列化學有限公司(紐交所:ICL)的確承擔了債務。但股東應該擔心它的債務使用嗎?

When Is Debt Dangerous?

債務何時會變得危險?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. When we think about a company's use of debt, we first look at cash and debt together.

當企業無法輕鬆履行其債務義務時,債務和其他負債變得風險多多,這些義務可能是通過自由現金流滿足,也可能是以有吸引力的價格融資。最終,如果公司無法履行其償還債務的法律義務,股東可能會什麼都得不到。然而,更頻繁(但仍然代價高昂)發生的情況是,公司必須以非常低廉的價格發行股票,永久稀釋股東股份,僅僅是爲了修復其資產負債表。當然,債務的好處在於,它通常代表着廉價資本,特別是當它替代了一家可以以高回報率進行再投資的公司中的稀釋時。當我們考慮一家公司對債務的使用時,我們首先將現金和債務結合在一起。

How Much Debt Does ICL Group Carry?

ICL Group負擔了多少債務?

You can click the graphic below for the historical numbers, but it shows that ICL Group had US$2.45b of debt in September 2024, down from US$2.58b, one year before. On the flip side, it has US$503.0m in cash leading to net debt of about US$1.95b.

您可以點擊下面的圖形查看歷史數字,但它顯示,2024年9月以色列化學的債務爲24.5億美元,較一年前的25.8億美元有所下降。另一方面,它持有現金50300萬美元,導致淨債務約爲19.5億美元。

big
NYSE:ICL Debt to Equity History November 19th 2024
紐交所:ICL債務與股本歷史 2024年11月19日

How Healthy Is ICL Group's Balance Sheet?

以色列化學的資產負債表健康嗎?

We can see from the most recent balance sheet that ICL Group had liabilities of US$2.45b falling due within a year, and liabilities of US$2.97b due beyond that. On the other hand, it had cash of US$503.0m and US$1.39b worth of receivables due within a year. So it has liabilities totalling US$3.53b more than its cash and near-term receivables, combined.

我們可以從最近的資產負債表中看到,以色列化學的流動負債爲24.5億美元,非流動負債爲29.7億美元。另一方面,它有現金50300萬和價值13.9億美元的應收款項,均在一年內到期。因此,它的負債總額比現金和短期應收款總和多出35.3億美元。

This is a mountain of leverage relative to its market capitalization of US$5.70b. Should its lenders demand that it shore up the balance sheet, shareholders would likely face severe dilution.

這與其57億美元的市值相比,形成了一個巨大的槓桿。如果其貸款方要求其改善資產負債表,股東可能會面臨嚴重的稀釋。

We use two main ratios to inform us about debt levels relative to earnings. The first is net debt divided by earnings before interest, tax, depreciation, and amortization (EBITDA), while the second is how many times its earnings before interest and tax (EBIT) covers its interest expense (or its interest cover, for short). This way, we consider both the absolute quantum of the debt, as well as the interest rates paid on it.

我們使用兩個主要比率來了解相對於收益的債務水平。第一個是淨債務除以息稅折舊攤銷前利潤(EBITDA),而第二個是它的息稅前利潤(EBIT)覆蓋其利息支出的次數(或者簡稱爲利息覆蓋率)。這樣,我們同時考慮債務的絕對數量以及所支付的利率。

ICL Group's net debt of 1.6 times EBITDA suggests graceful use of debt. And the fact that its trailing twelve months of EBIT was 9.0 times its interest expenses harmonizes with that theme. It is just as well that ICL Group's load is not too heavy, because its EBIT was down 50% over the last year. Falling earnings (if the trend continues) could eventually make even modest debt quite risky. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine ICL Group's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

以色列化學的淨債務爲EBITDA的1.6倍,這表明其債務使用得當。並且,其過去12個月的EBIT是利息支出的9.0倍,這與該主題一致。以色列化學的負擔並不太重,因爲其EBIT在過去一年下降了50%。持續下降的收益可能最終使得即使是適度的債務也構成相當大的風險。在分析債務水平時,資產負債表顯然是一個開始的地方。但未來的收益才是決定以色列化學未來維持健康資產負債表能力的關鍵。因此,如果你關注未來,可以查看這份免費的報告,顯示分析師的利潤預測。

Finally, a company can only pay off debt with cold hard cash, not accounting profits. So we clearly need to look at whether that EBIT is leading to corresponding free cash flow. In the last three years, ICL Group's free cash flow amounted to 50% of its EBIT, less than we'd expect. That weak cash conversion makes it more difficult to handle indebtedness.

最後,公司只能用現金償還債務,而不是會計利潤。因此,我們顯然需要看看EBIT是否帶來了相應的自由現金流。在過去三年中,以色列化學的自由現金流佔其EBIT的50%,低於我們的預期。這種低現金轉化使得償還債務變得更加困難。

Our View

我們的觀點

ICL Group's struggle to grow its EBIT had us second guessing its balance sheet strength, but the other data-points we considered were relatively redeeming. For example, its interest cover is relatively strong. Taking the abovementioned factors together we do think ICL Group's debt poses some risks to the business. While that debt can boost returns, we think the company has enough leverage now. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. For example, we've discovered 2 warning signs for ICL Group that you should be aware of before investing here.

以色列化學在提高EBIT方面的掙扎讓我們對其資產負債表的強度產生了懷疑,但我們考慮的其他數據點相對令人寬慰。 例如,其利息保障倍數相對較強。 將上述因素綜合考慮,我們確實認爲以色列化學的債務對該業務構成了一定風險。 雖然這項債務可以提升回報,但我們認爲公司現在槓桿足夠。 毫無疑問,我們從資產負債表中學到的最多關於債務的知識。 但最終,每家公司都可能含有存在於資產負債表之外的風險。 例如,我們發現了以色列化學的兩個警告信號,您在此投資前應當留意。

If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.

If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論